Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

Autor: Irene Hernandez, J. Hernando, Oriol Mirallas, Elena Martínez-Sáez, Anas Chaachou, A. Garcia-Alvarez, Betina Biagetti, Francesca Filippi-Arriaga, Anton Aubanell, Jaume Capdevila
Přispěvatelé: Institut Català de la Salut, [Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Filippi-Arriaga F] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernandez Hernandez I, Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chaachou A, Martínez-Saez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Hipòfisi - Tumors - Tractament
Adenoma
Male
medicine.medical_specialty
Side effect
Endocrinology
Diabetes and Metabolism

medicine.medical_treatment
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Case Report
Disease
temozolomide
aggressive pituitary tumors
Adenoma - Tractament
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Quimioteràpia combinada
Diseases of the endocrine glands. Clinical endocrinology
Neoplasms::Neoplasms by Histologic Type::Neoplasms
Glandular and Epithelial::Adenoma [DISEASES]

Nelson Syndrome
Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Pituitary Neoplasms::ACTH-Secreting Pituitary Adenoma::Nelson Syndrome [DISEASES]
Capecitabine
Endocrinology
Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL
DIAGNOSTIC AND THERAPEUTIC TECHNIQUES
AND EQUIPMENT]

Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
Neoplasm Invasiveness
Pituitary Neoplasms
neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma [ENFERMEDADES]
Adverse effect
Chemotherapy
Temozolomide
Nelson’s syndrome
business.industry
capecitabine
Pituitary tumors
Nelson's syndrome
terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS
DIAGNÓSTICOS Y TERAPÉUTICOS]

Middle Aged
medicine.disease
RC648-665
Surgery
Tumor Burden
Treatment Outcome
neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias hipofisarias::adenoma hipofisario secretor de ACTH::síndrome de Nelson [ENFERMEDADES]
Spain
business
medicine.drug
Zdroj: Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 12 (2021)
Scientia
ISSN: 1664-2392
Popis: Agressive pituitary tumors; Capecitabine; Temozolomide Tumores hipofisarios agresivos; Capecitabina; Temozolomida Tumors hipofisaris agressius; Capecitabina; Temozolomida Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
Databáze: OpenAIRE